-Takeshi Iwatsubo Researcher Activity Profile

Research Author Detailed Information 

Takeshi Iwatsubo Publication Rate By Year

Takeshi Iwatsubo has published 1 paper(s) in 1997, 13 paper(s) in 2007, 4 paper(s) in 2008, for a total of 18 research publications in total.

Takeshi T Iwatsubo Author Information

LAST NAME: iwatsubo

FIRST NAME: Takeshi

INITIALS: t

AFFILIATION:

Papers

Takeshi Iwatsubo's Publication Record

1. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Abeta fibril formation without increasing protofibril formation. Year Published: 2007
Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
2. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Year Published: 2007
Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA. clippa@drexelmed.edu
3. Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein. Year Published: 2007
Department of Structural Biology and Biomolecular Engineering, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.
4. Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. Year Published: 2007
Department of Molecular Neurobiology, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan.
5. Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease. Year Published: 2007
Department of Molecular Neuroscience, Center for Bioresources, Niigata University, Niigata 951-8585, Japan.
6. Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein. Year Published: 2007
Department of Structural Biology and Biomolecular Engineering, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.
7. Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography. Year Published: 2007
Drug Metabolism Research Laboratories, Astellas Pharma Inc., 1-8, Azusawa 1-chome, Itabashi-ku, Tokyo 174-8511, Japan.
8. Pathological biochemistry of alpha-synucleinopathy. Year Published: 2007
Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan. iwatsubo@mol.f.u-tokyo.ac.jp
9. Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography. Year Published: 2007
Drug Metabolism Research Laboratories, Astellas Pharma Inc., 1-8, Azusawa 1-chome, Itabashi-ku, Tokyo 174-8511, Japan. takamitsu.yanagihara@jp.astellas.com
10. Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography. Year Published: 2007
Drug Metabolism Research Laboratories, Astellas Pharma Inc., 1-8, Azusawa 1-chome, Itabashi-ku, Tokyo 174-8511, Japan. takamitsu.yanagihara@jp.astellas.com
11. Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease. Year Published: 2007
Department of Molecular Neuroscience, Center for Bioresources, Niigata University, Niigata 951-8585, Japan.
12. Cytoplasmic localization and proteasomal degradation of N-terminally cleaved form of PINK1. Year Published: 2008
Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
13. Functional Involvement of the Organic Cation Transporter 2 (rOct2) in the Renal Uptake of Organic Cations in Rats. Year Published: 2008
Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tokyo, Japan.
14. Pathological biochemistry of alpha-synucleinopathy. Year Published: 2007
Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan. iwatsubo@mol.f.u-tokyo.ac.jp
15. Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein. Year Published: 2007
Department of Structural Biology and Biomolecular Engineering, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.
16. Subpial amyloid plaques in the cerebellum in a case of Alzheimer's disease. Year Published: 1997
Division of Clinical Research, Kikuchi National Hospital, Kumamoto, Japan.
17. ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1-40) at the blood-brain barrier. Year Published: 2008
Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
18. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Year Published: 2008
Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan; Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo, 156-8585, Japan.